Asia-Pacific Early Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), by Toxicity Endpoint (Genotoxicity, Dermal Toxicity, Skin Toxicity, Ocular Toxicity, Phototoxicity, and Others), by End User (Pharmaceutical Industry, Cosmetic Industry, Chemical Industry, Food Industry, and Others) – Opportunity Analysis and Industry Forecast, 2023-2030

Asia-Pacific Early Toxicity Testing Market

Industry:  Life Sciences & Healthcare | Publish Date: Aug 2023 | No of Pages:  150 | No. Tables:  124 | No. Figures:  73

Market Definition

Asia-Pacific Early Toxicity Testing Market was valued at USD 5.10 billion in 2022 and is predicted to reach USD 7.55 billion by 2030, with a CAGR of 4.33% from 2023 to 2030.

Early toxicity testing is a crucial procedure that entails the assessment of potential harmful effects or toxicity associated with drugs, chemicals, or other substances during their initial developmental stages.

This evaluation is commonly conducted using in vitro studies (in controlled environments outside living organisms) or through animal models before progressing to human trials.

The primary objective of early toxicity testing is to detect any safety-related issues linked to a substance, determining its suitability for further development and testing. 

By conducting these tests upfront, the potential risks to both humans and animals in subsequent clinical trials can be minimized, leading to cost and time savings in the drug development process.

The range of assessments encompasses various examinations, including cell viability assays, genotoxicity evaluations, and studies on how the substance is processed within the body (pharmacokinetics). The selection of specific tests and methodologies is contingent on the substance's nature and its intended application.

Overall, early toxicity testing stands as a pivotal stride in the drug development trajectory, ensuring the safety and effectiveness of emerging drugs and substances before attaining approval for human use.

Dynamic Growth of the Asia-Pacific Market: Research, Development, and Pharmaceutical Expansion

Asia-Pacific consists of several countries such as Japan, China, India, Australia and Rest of Asia-Pacific. Several factors contribute to the rapid growth of the market in this region, including a focus on research and development and growth in the pharmaceutical industry is expected to drive the growth of the early toxicity testing market.

According to the National Center for Biotechnology Information, as of March 2021, the Asia-Pacific pharmaceutical industry is growing at an annual rate of 5.8% since 2017.

 

Fueled by Health Challenges: Elevating Early Toxicity Testing Market in the Asia-Pacific

The rise in prevalence of chronic diseases such as cancer and cardiovascular diseases in Asia-Pacific has led to an increase in drug development, thus driving the early toxicity testing market in the region.

Pharmaceutical companies are investing heavily in research and development to find new and effective treatments for these diseases.

As a result, demand for early toxicity testing services has also increased as it plays a crucial role in ensuring safety and efficacy of new drugs before they can be brought to the market. Hence, such factors propel the early toxicity testing market growth.

 

Impact of Regulatory Constraints on the Expansion of the Early Toxicity Testing Market in Asia-Pacific

However, strict guidelines established by regulatory agencies like the US FDA and the EMA necessitate extensive and exacting testing for medication development and safety, which can be costly and time-consuming and impede market expansion.

Small and medium-sized businesses that may lack the means to conduct thorough testing may find it difficult and expensive to comply with these rules.

Because of this, some businesses might decide to postpone or scrap drug development initiatives, which could reduce the market for early toxicity testing services.

Furthermore, strict rules may lead to a protracted approval procedure for new pharmaceuticals, which would add to the delay in the time it takes for drugs to reach the market. This, in turn, is expected to hamper the growth of the ETT market.

Technological Advancements in the field of Early Toxicity Testing Market in Asia-Pacific

Introduction of new technologies such as in-vitro modelling using 3D cell culture is expected to provide new lucrative opportunities for the early toxicity testing market during the forecast period.

Use of 3D cell cultures can better mimic complexity of tissues and organs, providing more accurate and reliable results for toxicity testing.

Traditional 2D cell culture models are limited in their ability to mimic the complexity of human tissues and organs, often leading to inaccurate and unreliable results in toxicity testing. 

However, use of 3D cell culture models can better mimic structural and functional complexity of tissues and organs, providing more accurate and reliable results for toxicity testing.

3D cell cultures allow growth and interaction of multiple cell types, creating a microenvironment that more closely resembles human tissues and organs. This can better predict the toxic effects of drugs and chemicals in the human body, reducing the risk of adverse effects in clinical trials. Hence, such factors propel the market growth.

 

Competitive Landscape  

The Asia-Pacific early toxicity testing industry includes several market players such as Inotiv Inc., Bio-Rad Laboratories Inc, Evotec A.G., Agilent Technologies Inc, Wuxi Apptec, Bruker, Perkinelmer Inc., Enzo Biochem Inc., Danaher Corporation, Eurofins Scientific SE, Charles River Laboratories International, Inc., Labcorp Drug Development., Promega Corporation, Insphero AG. and Thermo Fisher Scientific Inc.

KEY BENEFITS

  • The Asia-Pacific early toxicity testing market report provides a quantitative analysis of the current market and estimations through 2023-2030 that assists in identifying the prevailing market opportunities to capitalize on.

  • The study comprises a deep dive analysis of the market trend including the current and future trends for depicting the prevalent investment pockets in the industry.

  • The information related to key drivers, restraints, and opportunities and their impact on the market is provided in the report.

  • The competitive analysis of the key players along with their market share in the Asia-Pacific early toxicity testing market.

  • The SWOT analysis and Porter’s Five Forces model are elaborated in the study.

  • Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

ASIA-PACIFIC EARLY TOXICITY TESTING MARKET KEY SEGMENTS

By Technique

  • In Vivo

  • In Vitro

    • Cell Culture    

    • PCR    

    • ELISA    

    • Western Blotting    

    • Protein Binding Assays    

  • In Silico    

By Toxicity Endpoint

  • Genotoxicity    

  • Dermal Toxicity 

  • Skin Toxicity 

  • Ocular Toxicity    

  • Phototoxicity    

  • Others    

By End User

  • Pharmaceutical Industry    

  • Cosmetic Industry    

  • Chemical Industry    

  • Food Industry     

  • Others       

By Geography

  • Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Indonesia

    • Singapore

    • Taiwan

    • Thailand

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2022

USD 5.10 Billion

Revenue Forecast in 2030

USD 7.55 Billion

Growth Rate

CAGR of 4.33% from 2023 to 2030

Analysis Period

2022–2030

Base Year Considered

2022

Forecast Period

2023–2030

Market Size Estimation

Billion (USD)

Growth Factors

The presence of major pharmaceutical companies.

The demand for personalized medicine.

Countries Covered

9

Companies Profiled

15

Market Share

Available for 10 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

Test

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2       ASIA-PACIFIC EARLY TOXICITY TESTING MARKET BY TECHNIQUE

           2.1      OVERVIEW

           2.2      IN VIVO

                         2.2.1      IN VIVO MARKET, BY COUNTRY

           2.3      IN VITRO

                         2.3.1      IN VITRO MARKET, BY TECHNIQUE

                                          2.3.1.1      CELL CULTURE MARKET, BY COUNTRY

                                          2.3.1.2      PCR MARKET, BY COUNTRY

                                          2.3.1.3      ELISA MARKET, BY COUNTRY

                                          2.3.1.4      WESTERN BLOTTING MARKET, BY COUNTRY

                                          2.3.1.5      PROTEIN BINDING ASSAYS MARKET, BY COUNTRY

                         2.3.2      IN VITRO MARKET, BY COUNTRY

           2.4      IN SILICO

                         2.4.1      IN SILICO MARKET, BY COUNTRY

3      ASIA-PACIFIC EARLY TOXICITY TESTING MARKET BY TOXICITY ENDPOINT

           3.1      OVERVIEW

           3.2      GENOTOXICITY

                         3.2.1      GENOTOXICITY MARKET, BY COUNTRY

           3.3      DERMAL TOXICITY

                         3.3.1      DERMAL TOXICITY MARKET, BY COUNTRY

           3.4      SKIN TOXICITY

                         3.4.1      SKIN TOXICITY MARKET, BY COUNTRY

           3.5      OCULAR TOXICITY

                         3.5.1      OCULAR TOXICITY MARKET, BY COUNTRY

           3.6      PHOTOTOXICITY

                         3.6.1      PHOTOTOXICITY MARKET, BY COUNTRY

           3.7      OTHERS

                         3.7.1      OTHERS MARKET, BY COUNTRY

4      ASIA-PACIFIC EARLY TOXICITY TESTING MARKET BY END USER

           4.1      OVERVIEW

           4.2      PHARMACEUTICAL INDUSTRY

                         4.2.1      PHARMACEUTICAL INDUSTRY MARKET, BY COUNTRY

           4.3      COSMETIC INDUSTRY

                         4.3.1      COSMETIC INDUSTRY MARKET, BY COUNTRY

           4.4      CHEMICAL INDUSTRY

                         4.4.1      CHEMICAL INDUSTRY MARKET, BY COUNTRY

           4.5      FOOD INDUSTRY

                         4.5.1      FOOD INDUSTRY MARKET, BY COUNTRY

           4.6      OTHERS

                         4.6.1      OTHERS MARKET, BY COUNTRY

5       ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY

           5.1     OVERVIEW

           5.2     AUSTRALIA

                         5.2.1     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.2.2     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.2.3     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER

           5.3     CHINA

                         5.3.1     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.3.2     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.3.3     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER

           5.4     INDIA

                         5.4.1     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.4.2     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.4.3     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER

           5.5     JAPAN

                         5.5.1     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.5.2     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.5.3     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER

           5.6     SOUTH KOREA

                         5.6.1     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.6.2     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.6.3     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER

           5.7     INDONESIA

                         5.7.1     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.7.2     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.7.3     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER

           5.8     SINGAPORE

                         5.8.1     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.8.2     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.8.3     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER

           5.9     TAIWAN

                         5.9.1     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.9.2     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.9.3     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER

           5.10     THAILAND

                         5.10.1     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.10.2     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.10.3     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER

           5.11     REST OF ASIA-PACIFIC

                         5.11.1     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.11.2     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.11.3     ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER

6      COMPANY PROFILES

           6.1   INOTIV INC.

                         6.1.1   COMPANY OVERVIEW

                         6.1.2   COMPANY SNAPSHOT

                         6.1.3   OPERATING BUSINESS SEGMENTS

                         6.1.4   PRODUCT PORTFOLIO

                         6.1.5   BUSINESS PERFORMANCE

                         6.1.6   BUSINESS SEGMENTS

                         6.1.7   GEOGRAPHIC SEGMENTS

                         6.1.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.1.9   PRIMARY MARKET COMPETITORS

           6.2   BIO-RAD LABORATORIES INC.

                         6.2.1   COMPANY OVERVIEW

                         6.2.2   COMPANY SNAPSHOT

                         6.2.3   OPERATING BUSINESS SEGMENTS

                         6.2.4   PRODUCT PORTFOLIO

                         6.2.5   BUSINESS PERFORMANCE

                         6.2.6   BUSINESS SEGMENTS

                         6.2.7   GEOGRAPHIC SEGMENTS

                         6.2.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.2.9   PRIMARY MARKET COMPETITORS

           6.3   EVOTEC A.G.

                         6.3.1   COMPANY OVERVIEW

                         6.3.2   COMPANY SNAPSHOT

                         6.3.3   OPERATING BUSINESS SEGMENTS

                         6.3.4   PRODUCT PORTFOLIO

                         6.3.5   BUSINESS PERFORMANCE

                         6.3.6   BUSINESS SEGMENTS

                         6.3.7   GEOGRAPHIC SEGMENTS

                         6.3.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.3.9   PRIMARY MARKET COMPETITORS

           6.4   AGILENT TECHNOLOGIES INC.

                         6.4.1   COMPANY OVERVIEW

                         6.4.2   COMPANY SNAPSHOT

                         6.4.3   OPERATING BUSINESS SEGMENTS

                         6.4.4   PRODUCT PORTFOLIO

                         6.4.5   BUSINESS PERFORMANCE

                         6.4.6   BUSINESS SEGMENTS

                         6.4.7   GEOGRAPHIC SEGMENTS

                         6.4.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.4.9   PRIMARY MARKET COMPETITORS

           6.5   WUXI APPTEC

                         6.5.1   COMPANY OVERVIEW

                         6.5.2   COMPANY SNAPSHOT

                         6.5.3   OPERATING BUSINESS SEGMENTS

                         6.5.4   PRODUCT PORTFOLIO

                         6.5.5   BUSINESS PERFORMANCE

                         6.5.6   BUSINESS SEGMENTS

                         6.5.7   GEOGRAPHIC SEGMENTS

                         6.5.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.5.9   PRIMARY MARKET COMPETITORS

           6.6   BRUKER

                         6.6.1   COMPANY OVERVIEW

                         6.6.2   COMPANY SNAPSHOT

                         6.6.3   OPERATING BUSINESS SEGMENTS

                         6.6.4   PRODUCT PORTFOLIO

                         6.6.5   BUSINESS PERFORMANCE

                         6.6.6   BUSINESS SEGMENTS

                         6.6.7   GEOGRAPHIC SEGMENTS

                         6.6.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.6.9   PRIMARY MARKET COMPETITORS

           6.7   PERKINELMER INC.

                         6.7.1   COMPANY OVERVIEW

                         6.7.2   COMPANY SNAPSHOT

                         6.7.3   OPERATING BUSINESS SEGMENTS

                         6.7.4   PRODUCT PORTFOLIO

                         6.7.5   BUSINESS PERFORMANCE

                         6.7.6   BUSINESS SEGMENTS

                         6.7.7   GEOGRAPHIC SEGMENTS

                         6.7.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.7.9   PRIMARY MARKET COMPETITORS

           6.8   ENZO BIOCHEM INC.

                         6.8.1   COMPANY OVERVIEW

                         6.8.2   COMPANY SNAPSHOT

                         6.8.3   OPERATING BUSINESS SEGMENTS

                         6.8.4   PRODUCT PORTFOLIO

                         6.8.5   BUSINESS PERFORMANCE

                         6.8.6   BUSINESS SEGMENTS

                         6.8.7   GEOGRAPHIC SEGMENTS

                         6.8.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.8.9   PRIMARY MARKET COMPETITORS

           6.9   DANAHER CORPORATION

                         6.9.1   COMPANY OVERVIEW

                         6.9.2   COMPANY SNAPSHOT

                         6.9.3   OPERATING BUSINESS SEGMENTS

                         6.9.4   PRODUCT PORTFOLIO

                         6.9.5   BUSINESS PERFORMANCE

                         6.9.6   BUSINESS SEGMENTS

                         6.9.7   GEOGRAPHIC SEGMENTS

                         6.9.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.9.9   PRIMARY MARKET COMPETITORS

           6.10   EUROFINS SCIENTIFIC SE

                         6.10.1   COMPANY OVERVIEW

                         6.10.2   COMPANY SNAPSHOT

                         6.10.3   OPERATING BUSINESS SEGMENTS

                         6.10.4   PRODUCT PORTFOLIO

                         6.10.5   BUSINESS PERFORMANCE

                         6.10.6   BUSINESS SEGMENTS

                         6.10.7   GEOGRAPHIC SEGMENTS

                         6.10.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.10.9   PRIMARY MARKET COMPETITORS

           6.11   CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

                         6.11.1   COMPANY OVERVIEW

                         6.11.2   COMPANY SNAPSHOT

                         6.11.3   OPERATING BUSINESS SEGMENTS

                         6.11.4   PRODUCT PORTFOLIO

                         6.11.5   BUSINESS PERFORMANCE

                         6.11.6   BUSINESS SEGMENTS

                         6.11.7   GEOGRAPHIC SEGMENTS

                         6.11.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.11.9   PRIMARY MARKET COMPETITORS

           6.12   LABCORP DRUG DEVELOPMENT.

                         6.12.1   COMPANY OVERVIEW

                         6.12.2   COMPANY SNAPSHOT

                         6.12.3   OPERATING BUSINESS SEGMENTS

                         6.12.4   PRODUCT PORTFOLIO

                         6.12.5   BUSINESS PERFORMANCE

                         6.12.6   BUSINESS SEGMENTS

                         6.12.7   GEOGRAPHIC SEGMENTS

                         6.12.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.12.9   PRIMARY MARKET COMPETITORS

           6.13   PROMEGA CORPORATION

                         6.13.1   COMPANY OVERVIEW

                         6.13.2   COMPANY SNAPSHOT

                         6.13.3   OPERATING BUSINESS SEGMENTS

                         6.13.4   PRODUCT PORTFOLIO

                         6.13.5   BUSINESS PERFORMANCE

                         6.13.6   BUSINESS SEGMENTS

                         6.13.7   GEOGRAPHIC SEGMENTS

                         6.13.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.13.9   PRIMARY MARKET COMPETITORS

           6.14   INSPHERO AG

                         6.14.1   COMPANY OVERVIEW

                         6.14.2   COMPANY SNAPSHOT

                         6.14.3   OPERATING BUSINESS SEGMENTS

                         6.14.4   PRODUCT PORTFOLIO

                         6.14.5   BUSINESS PERFORMANCE

                         6.14.6   BUSINESS SEGMENTS

                         6.14.7   GEOGRAPHIC SEGMENTS

                         6.14.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.14.9   PRIMARY MARKET COMPETITORS

           6.15   THERMO FISHER SCIENTIFIC INC.

                         6.15.1   COMPANY OVERVIEW

                         6.15.2   COMPANY SNAPSHOT

                         6.15.3   OPERATING BUSINESS SEGMENTS

                         6.15.4   PRODUCT PORTFOLIO

                         6.15.5   BUSINESS PERFORMANCE

                         6.15.6   BUSINESS SEGMENTS

                         6.15.7   GEOGRAPHIC SEGMENTS

                         6.15.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.15.9   PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 2. ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 3. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 4. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 5. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

TABLE 6. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 7. AUSTRALIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 8. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 9. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 10. CHINA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 11. CHINA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 12. CHINA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 13. CHINA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 14. INDIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 15. INDIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 16. INDIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 17. INDIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 18. INDONESIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 19. INDONESIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 20. INDONESIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 21. INDONESIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 22. JAPAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 23. JAPAN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 24. JAPAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 25. JAPAN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 26. SINGAPORE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 27. SINGAPORE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 28. SINGAPORE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 29. SINGAPORE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 30. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 31. SOUTH KOREA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 32. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 33. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 34. TAIWAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 35. TAIWAN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 36. TAIWAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 37. TAIWAN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 38. THAILAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 39. THAILAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 40. THAILAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 41. THAILAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 42. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 43. REST OF ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 44. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 45. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 46. INOTIV INC.: COMPANY SNAPSHOT

TABLE 47. INOTIV INC: OPERATING SEGMENTS

TABLE 48. INOTIV INC.: PR0DUCT PORTFOLIO

TABLE 49. INOTIV INC.: BUSINESS SEGMENT

TABLE 50. INOTIV INC.: GEOGRAPHIC SEGMENT

TABLE 51. INOTIV INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 52. BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT

TABLE 53. BIO-RAD LABORATORIES INC: OPERATING SEGMENTS

TABLE 54. BIO-RAD LABORATORIES INC: PRODUCT PORTFOLIO

TABLE 55. BIO-RAD LABORATORIES INC: BUSINESS SEGMENT

TABLE 56. BIO-RAD LABORATORIES INC: GEOGRAPHIC SEGMENT

TABLE 57. BIO-RAD LABORATORIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 58. EVOTEC A.G.: COMPANY SNAPSHOT

TABLE 59. EVOTEC A.G.: OPERATING SEGMENTS

TABLE 60. EVOTEC A.G.: PRODUCT PORTFOLIO

TABLE 61. EVOTEC A.G.: BUSINESS SEGMENT

TABLE 62. EVOTEC A.G.: GEOGRAPHIC SEGMENT

TABLE 63. EVOTEC A.G.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 64. AGILENT TECHNOLOGIES INC: COMPANY SNAPSHOT

TABLE 65. AGILENT TECHNOLOGIES INC: OPERATING SEGMENTS

TABLE 66. AGILENT TECHNOLOGIES INC: PRODUCT PORTFOLIO

TABLE 67. AGILENT TECHNOLOGIES INC: BUSINESS SEGMENT

TABLE 68. AGILENT TECHNOLOGIES INC: GEOGRAPHIC SEGMENT

TABLE 69. AGILENT TECHNOLOGIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 70. WUXI APPTEC.: COMPANY SNAPSHOT

TABLE 71. WUXI APPTEC: OPERATING SEGMENTS

TABLE 72. WUXI APPTEC.: PR0DUCT PORTFOLIO

TABLE 73. WUXI APPTEC.: BUSINESS SEGMENT

TABLE 74. WUXI APPTEC.: GEOGRAPHIC SEGMENT

TABLE 75. WUXI APPTEC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 76. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT

TABLE 77. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS

TABLE 78. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO

TABLE 79. THERMO FISHER SCIENTIFIC: BUSINESS SEGMENT

TABLE 80. THERMO FISHER SCIENTIFIC: GEOGRAPHIC SEGMENT

TABLE 81. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 82. BRUKER: COMPANY SNAPSHOT

TABLE 83. BRUKER: OPERATING SEGMENTS

TABLE 84. BRUKER: PRODUCT PORTFOLIO

TABLE 85. BRUKER: BUSINESS SEGMENT

TABLE 86. BRUKER: GEOGRAPHIC SEGMENT

TABLE 87. BRUKER: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 88. PERKINELMER INC.: COMPANY SNAPSHOT

TABLE 89. PERKINELMER INC.: OPERATING SEGMENTS

TABLE 90. PERKINELMER INC.: PRODUCT PORTFOLIO

TABLE 91. PERKINELMER INC.: BUSINESS SEGMENT

TABLE 92. PERKINELMER INC.: GEOGRAPHIC SEGMENT

TABLE 93. PERKINELMER INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 94. ENZO BIOCHEM INC.: COMPANY SNAPSHOT

TABLE 95. ENZO BIOCHEM INC.: OPERATING SEGMENTS

TABLE 96. ENZO BIOCHEM INC.: PRODUCT PORTFOLIO

TABLE 97. ENZO BIOCHEM INC.: BUSINESS SEGMENT

TABLE 98. ENZO BIOCHEM INC.: GEOGRAPHIC SEGMENT

TABLE 99. ENZO BIOCHEM INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 100. DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 101. DANAHER CORPORATION: OPERATING SEGMENTS

TABLE 102. DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 103. DANAHER CORPORATION: BUSINESS SEGMENT

TABLE 104. DANAHER CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 105. EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT

TABLE 106. EUROFINS SCIENTIFIC SE: PRODUCT PORTFOLIO

TABLE 107. EUROFINS SCIENTIFIC SE: GEOGRAPHIC SEGMENT

TABLE 108. EUROFINS SCIENTIFIC SE: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 109. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT

TABLE 110. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS

TABLE 111. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO

TABLE 112. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS SEGMENT

TABLE 113. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: GEOGRAPHIC SEGMENT

TABLE 114. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 115. LABCORP DRUG DEVELOPMENT.: COMPANY SNAPSHOT

TABLE 116. LABCORP DRUG DEVELOPMENT.: OPERATING SEGMENTS

TABLE 117. LABCORP DRUG DEVELOPMENT.: PRODUCT PORTFOLIO

TABLE 118. LABCORP DRUG DEVELOPMENT.: BUSINESS SEGMENT

TABLE 119. LABCORP DRUG DEVELOPMENT.: GEOGRAPHIC SEGMENT

TABLE 120. LABCORP DRUG DEVELOPMENT.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 121. PROMEGA CORPORATION: COMPANY SNAPSHOT

TABLE 122. PROMEGA CORPORATION: PRODUCT PORTFOLIO

TABLE 123. INSPHERO AG: COMPANY SNAPSHOT

TABLE 124. INSPHERO AG: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 2. ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 3. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 4. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 5. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 6. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 7. AUSTRALIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 8. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 9. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 10. CHINA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 11. CHINA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 12. CHINA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 13. CHINA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 14. INDIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 15. INDIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 16. INDIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 17. INDIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 18. INDONESIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 19. INDONESIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 20. INDONESIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 21. INDONESIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 22. JAPAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 23. JAPAN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 24. JAPAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 25. JAPAN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 26. SINGAPORE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 27. SINGAPORE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 28. SINGAPORE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 29. SINGAPORE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 30. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 31. SOUTH KOREA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 32. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 33. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 34. TAIWAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 35. TAIWAN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 36. TAIWAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 37. TAIWAN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 38. THAILAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 39. THAILAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 40. THAILAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 41. THAILAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 42. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 43. REST OF ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 44. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 45. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 46. INOTIV INC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 47. INOTIV INC: PRIMARY MARKET COMPETITORS

FIGURE 48. BIO-RAD LABORATORIES INC CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 49. BIO-RAD LABORATORIES INC: PRIMARY MARKET COMPETITORS

FIGURE 50. EVOTEC A.G.: NET SALES, 2019–2021 ($MILLION)

FIGURE 51. EVOTEC A.G.: PRIMARY MARKET COMPETITORS

FIGURE 52. AGILENT TECHNOLOGIES INC: NET SALES, 2020–2022 ($MILLION)

FIGURE 53. AGILENT TECHNOLOGIES INC: PRIMARY MARKET COMPETITORS

FIGURE 54. WUXI APPTEC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 55. WUXI APPTEC: PRIMARY MARKET COMPETITORS

FIGURE 56. THERMO FISHER SCIENTIFIC: NET SALES, 2019–2021 ($MILLION)

FIGURE 57. THERMO FISHER SCIENTIFIC: PRIMARY MARKET COMPETITORS

FIGURE 58. BRUKER: NET SALES, 2019–2021 ($MILLION)

FIGURE 59. BRUKER: PRIMARY MARKET COMPETITORS

FIGURE 60. PERKINELMER INC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 61. PERKINELMER INC.: PRIMARY MARKET COMPETITORS

FIGURE 62. ENZO BIOCHEM INC.: NET SALES, 2019–2021 ($MILLION)

FIGURE 63. ENZO BIOCHEM INC.: PRIMARY MARKET COMPETITORS

FIGURE 64. DANAHER CORPORATION: NET SALES, 2020–2022 ($MILLION)

FIGURE 65. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 66. EUROFINS SCIENTIFIC SE CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 67. EUROFINS SCIENTIFIC SE: PRIMARY MARKET COMPETITORS

FIGURE 68. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 69. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRIMARY MARKET COMPETITORS

FIGURE 70. LABCORP DRUG DEVELOPMENT. CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 71. LABCORP DRUG DEVELOPMENT.: PRIMARY MARKET COMPETITORS

FIGURE 72. PROMEGA CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 73. INSPHERO AG: PRIMARY MARKET COMPETITORS

KEY PLAYERS

  • Inotiv Inc.

  • Bio-Rad Laboratories Inc

  • Evotec A.G. 

  • Agilent Technologies Inc

  • Wuxi Apptec

  • Bruker

  • Perkinelmer Inc.

  • Enzo Biochem Inc.

  • Danaher Corporation

  • Eurofins Scientific SE

  • Charles River Laboratories International, Inc.

  • Labcorp Drug Development.

  • Promega Corporation

  • Insphero AG

  • Thermo Fisher Scientific Inc.


Frequently Asked Questions
What will be the worth of Asia-Pacific early toxicity testing market by the end of 2030?

According to the report published by the Next Move Consulting, the Asia-Pacific early toxicity testing market business is expected to hit at $7.55 billion (USD) by 2030.

What are the leading companies in the Asia-Pacific early toxicity testing market?

The Asia-Pacific early toxicity testing industry includes several market players such as Inotiv Inc., Bio-Rad Laboratories Inc, Evotec A.G., Agilent Technologies Inc, Wuxi Apptec, Bruker, Perkinelmer Inc., Enzo Biochem Inc., Danaher Corporation, Eurofins Scientific SE, Charles River Laboratories International, Inc., Labcorp Drug Development., Promega Corporation, Insphero AG, and Thermo Fisher Scientific Inc.

What are the market segmentations and scope of the study for the Asia-Pacific early toxicity testing industry?

The Asia-Pacific early toxicity testing market share is segmented on the basis of type, application, power systems, and geography.

Which elements are contributing to the expansion of the early toxicity testing market in Asia-Pacific?

Factors contributing to the expansion of the early toxicity testing market in Asia-Pacific are research, development, and pharmaceutical expansion, prevalence of chronic diseases, and technological advancements.

What factors are limiting the growth of the Asia-Pacific early toxicity testing market?

The factors limiting the growth of the Asia-Pacific early toxicity testing market are stringent regulations and high cost of investments.